Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects

E-ISSN： 1873-4286|17|2|130-136

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.2, 2011-01, pp. : 130-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides

Current Drug Discovery Technologies, Vol. 6, Iss. 4, 2009-12 ,pp. : 241-251

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the kynurenine pathway

By Stone T.W.

European Journal of Medicinal Chemistry, Vol. 35, Iss. 2, 2000-02 ,pp. : 179-186

Elsevier

Access to resources Recommend Favorite

Kynurenine Pathway and Disease: An Overview

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 6, Iss. 6, 2007-12 ,pp. : 398-410

Bentham Science Publishers

Access to resources Recommend Favorite

Kynurenine Aminotransferases and the Prospects of Inhibitors for the Treatment of Schizophrenia

Current Medicinal Chemistry, Vol. 22, Iss. 24, 2015-01 ,pp. : 2902-2918

Bentham Science Publishers

Access to resources Recommend Favorite

The kynurenine pathway of tryptophan degradation as a drug target

By Schwarcz R.

Current Opinion in Pharmacology, Vol. 4, Iss. 1, 2004-02 ,pp. : 12-17

Elsevier

Access to resources Recommend Favorite